{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"}],"units":"Participants"}],"title":"Extension Week 48"},{"categories":[{"measurements":[{"groupId":"OG000","value":"12.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"}],"units":"Participants"}],"title":"Extension Week 72"},{"categories":[{"measurements":[{"groupId":"OG000","value":"50.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"}],"units":"Participants"}],"title":"Extension Week 96"}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"}],"units":"Participants"}],"description":"Tumor volume was evaluated by MRI. MRIs were performed and processed according to the guidelines of the central evaluator's facility. The pituitary adenomas were measured by a neuro-radiologist, using manual tracing together with the imaging analysis software. The largest diameter at any plan determined the maximum diameter of the tumor.","groups":[{"description":"All patients will receive pasireotide LAR (long acting release) 60 mg every 28 ± 3 days for 24 weeks","id":"OG000","title":"Pasireotide LAR"}],"paramType":"NUMBER","populationDescription":"number of participants with evaluable data varied across visits","reportingStatus":"POSTED","timeFrame":"baseline to week 48, 72, 96","title":"Percentage of Patients Achieving Tumour Volume Reduction in Extension Phase (FAS)","type":"SECONDARY","unitOfMeasure":"percentage of patients"}